(Public, NASDAQ:TSRO)   Watch this stock  
Find more results for TSRO
-3.29 (-3.92%)
Dec 15 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 77.20 - 83.27
52 week 77.20 - 192.94
Open 82.85
Vol / Avg. 1.92M/1.02M
Mkt cap 4.21B
P/E     -
Div/yield     -
EPS -8.43
Shares 54.38M
Beta 1.52
Inst. own 120%
Feb 26, 2018
Q4 2017 TESARO Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 13, 2017
TESARO Inc at Guggenheim Boston Healthcare Conference
Dec 7, 2017
TESARO Inc at Citi Global Healthcare Conference - Webcast
Nov 29, 2017
TESARO Inc at Evercore ISI Biopharma Catalyst/Deep Dive Conference
Nov 7, 2017
Q3 2017 TESARO Inc Earnings Call - Webcast
Nov 7, 2017
Q3 2017 TESARO Inc Earnings Release
Nov 7, 2017
TESARO Inc at Credit Suisse Healthcare Conference - Webcast
Sep 28, 2017
TESARO Inc at Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -17.71% -864.45%
Operating margin -15.47% -827.59%
EBITD margin - -778.39%
Return on average assets -15.23% -70.61%
Return on average equity -25.12% -108.39%
Employees 446 -
CDP Score - -


1000 Winter St Ste 3300
WALTHAM, MA 02451-1230
United States - Map
+1-339-9700900 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform. Rolapitant is a potent and long-acting neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Niraparib is an orally active and potent poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitor. It has various ongoing clinical trials evaluating niraparib for the treatment of ovarian or breast cancers. It has initiated a Phase I, dose escalation study for its first immuno-oncology antibody, TSR-042, which targets Programmed cell death protein 1. It has commenced pre-clinical research for its antibody candidate targeting Lymphocyte-activation gene-3 andTSR-033. It has commenced a Phase I clinical trial of TSR-042.

Officers and directors

David M. Mott Independent Chairman of the Board
Age: 51
Bio & Compensation  - Reuters
Mary Lynne Hedley Ph.D. President, Chief Operating Officer, Director
Age: 54
Bio & Compensation  - Reuters
Leon O. Moulder Jr. Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Timothy R. Pearson Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Age: 49
Bio & Compensation  - Reuters
Jeffrey H. Hanke Ph.D. Executive Vice President - Research and Development, Chief Scientific Officer
Age: 59
Bio & Compensation  - Reuters
Joseph L. Farmer Senior Vice President, General Counsel, Secretary
Age: 45
Bio & Compensation  - Reuters
Grant C. Bogle Senior Vice President, Chief Commercial Officer
Age: 59
Bio & Compensation  - Reuters
Martin H. Huber M.D. Senior Vice President and Chief Medical Officer
Age: 57
Bio & Compensation  - Reuters
Lawrence M. Alleva Independent Director
Age: 67
Bio & Compensation  - Reuters
James O. Armitage M.D. Independent Director
Age: 70
Bio & Compensation  - Reuters